Paola Guglielmelli

List of Publications by Year
in descending order

343 papers	19,316 citations	15001 68 h-index	14779 131 g-index
357 all docs	357 docs citations	357 times ranked	10720 citing authors

#	Article	IF	Citations
1	Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI). Leukemia and Lymphoma, 2022, 63, 189-198.	0.6	3
2	Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study. Blood Advances, 2022, 6, 373-375.	2.5	34
3	Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia. American Journal of Hematology, 2022, 97, E35.	2.0	18
4	Second versus first wave of COVID-19 in patients with MPN. Leukemia, 2022, 36, 897-900.	3.3	7
5	ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera. Blood Advances, 2022, 6, 2927-2931.	2.5	20
6	The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis. Antioxidants, 2022, 11, 113.	2.2	6
7	Portosystemic shunt is an effective treatment for complications of portal hypertension in hepatic myeloid metaplasia and improves nutritional status. Liver International, 2022, 42, 419-424.	1.9	4
8	Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera. Blood Cancer Journal, 2022, 12, 28.	2.8	31
9	Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis. American Journal of Hematology, 2022, 97, 846-855.	2.0	9
10	Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematology,the, 2022, 9, e301-e311.	2.2	46
11	JAK inhibitors and COVID-19. , 2022, 10, e002838.		34
12	Concomitant <scp>JAK2</scp> mutated myeloproliferative neoplasms and hereditary hemochromatosis. International Journal of Laboratory Hematology, 2022, 44, 999-1000.	0.7	1
13	Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance. Current Oncology, 2022, 29, 4970-4980.	0.9	2
14	SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates. American Journal of Hematology, 2022, 97, .	2.0	9
15	Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study. Leukemia and Lymphoma, 2021, 62, 918-926.	0.6	19
16	Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2P95-mutated neoplasms. Leukemia, 2021, 35, 2371-2381.	3.3	17
17	Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study. Leukemia, 2021, 35, 1121-1133.	3.3	61
18	BRAFV600E mutation in the wrong place: a case of concomitant polycythemia vera, hairy cell leukemia, and thyroid adenoma. Tumori, 2021, 107, NP28-NP32.	0.6	0

#	Article	IF	Citations
19	High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia, 2021, 35, 485-493.	3.3	70
20	Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosis. American Journal of Human Genetics, 2021, 108, 284-294.	2.6	12
21	Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. Blood Cancer Journal, 2021, 11, 21.	2.8	26
22	Lenalidomide: A doubleâ€edged sword for concomitant multiple myeloma and postâ€essential thrombocythemia myelofibrosis. American Journal of Hematology, 2021, 96, 749-754.	2.0	3
23	Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis. Blood Advances, 2021, 5, 1452-1462.	2.5	8
24	Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5	2.2	79
25	Mutations and thrombosis in essential thrombocythemia. Blood Cancer Journal, 2021, 11, 77.	2.8	26
26	Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs. Blood Advances, 2021, 5, 2184-2195.	2.5	12
27	Venetoclax with azacitidine or decitabine in blastâ€phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. American Journal of Hematology, 2021, 96, 781-789.	2.0	46
28	Long-term follow-up of recovered MPN patients with COVID-19. Blood Cancer Journal, 2021, 11, 115.	2.8	9
29	Pregnancy in patients with myelofibrosis: Mayoâ€“Florence series of 24 pregnancies in 16 women. British Journal of Haematology, 2021, 195, 133-137.	1.2	2
30	Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System lowâ€, intermediateâ€1â€, intermediateâ€2â€, and highâ€risk myelofibrosis in JUMP, a Phase 3b, expandedâ€access study. Hematological Oncology, 2021, 39, 558-566.	0.8	11
31	Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms. Cells, 2021, 10, 1962.	1.8	11
32	Impaired response to first <scp>SARSâ€CoV</scp>â€2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib. American Journal of Hematology, 2021, 96, E408-E410.	2.0	30
33	Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients. American Journal of Hematology, 2021, 96, 1472-1480.	2.0	20
34	Increased Plasma Levels of lncRNAs LINC01268, GAS5 and MALAT1 Correlate with Negative Prognostic Factors in Myelofibrosis. Cancers, 2021, 13, 4744.	1.7	9
35	Cerebral venous thrombosis and myeloproliferative neoplasms: A threeâ€center study of 74 consecutive cases. American Journal of Hematology, 2021, 96, 1580-1586.	2.0	13
36	AMELIORATE: early intensification in FLT3-mutated acute myeloid leukemia based on peripheral blast clearance â€“ÂMYNERVA-GIMEMA AML1919 trial. Future Oncology, 2021, 17, 3787-3796.	1.1	0

#	Article	IF	Citations
37	Neutrophil-to-Lymphocyte Ratio (NLR) Is a Risk Factor for Venous Thrombosis in Polycythemia Vera. Blood, 2021, 138, 1499-1499.	0.6	1
38	A JAK2V617F Variant Allele Frequency Greater Than 50% Identifies Patients with Polycythemia Vera at High Risk for Venous Thrombosis. Blood, 2021, 138, 237-237.	0.6	4
39	Screening for Hereditary Alpha-Tryptasemia in Subjects with Systemic Mastocytosis (SM) and Non-SM Mast Cell Activation Symptoms. Blood, 2021, 138, 1500-1500.	0.6	1
40	The Interaction between IPSS Score and JAK2 Mutation Identifies Patients at Different Vascular Risk in Primary Myelofibrosis. Blood, 2021, 138, 236-236.	0.6	2
41	A Globally Applicable "Triple AAA" Risk Model for Essential Thrombocythemia Based on Age, Absolute Neutrophil Count, and Absolute Lymphocyte Count. Blood, 2021, 138, 238-238.	0.6	2
42	Deciphering the Individual Contribution of Absolute Neutrophil, Lymphocyte and Monocyte Counts to Thrombosis Risk in Patients with Myeloproliferative Neoplasms. Blood, 2021, 138, 3651-3651.	0.6	1
43	Mutation Landscape and Prognostic Correlates of ASXL1 Variants in Primary and Secondary Myelofibrosis. Blood, 2021, 138, 2578-2578.	0.6	1
44	Second Versus First Wave of COVID-19 in Patients with MPN. Blood, 2021, 138, 315-315.	0.6	0
45	A Myelodepletive Phenotype Is Associated with Distinctive Molecular Features and Adverse Outcomes in Patients with Myelofibrosis. Blood, 2021, 138, 1498-1498.	0.6	6
46	Single Cell Mutation Analysis Delineates Clonal Architecture in Leukemic Transformation of Myeloproliferative Neoplasms. Blood, 2021, 138, 56-56.	0.6	1
47	Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRÎ±, PDGFRÎ², FGFR1 or PCM1-JAK2. Biomarker Research, 2021, 9, 83.	2.8	1
48	The MPL mutation. International Review of Cell and Molecular Biology, 2021, 365, 163-178.	1.6	5
49	JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis. Blood Cancer Journal, 2021, 11, 199.	2.8	47
50	Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms. American Journal of Hematology, 2020, 95, E23-E26.	2.0	8
51	Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. American Journal of Hematology, 2020, 95, 156-166.	2.0	53
52	Impact of bone marrow fibrosis grade in postâ€polycythemia vera and postâ€essential thrombocythemia myelofibrosis: A study of the MYSEC group. American Journal of Hematology, 2020, 95, E1-E3.	2.0	8
53	Second cancers in MPN: Survival analysis from an international study. American Journal of Hematology, 2020, 95, 295-301.	2.0	34
54	A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis. Blood Cancer Journal, 2020, 10, 100.	2.8	19

#	Article	IF	Citations
55	Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data . OncoTargets and Therapy, 2020, Volume 13, 12367-12382.	1.0	39
56	The HScore for secondary hemophagocytic lymphohistiocytosis, calculated without a marrow biopsy, is consistently low in patients with COVIDâ€19. International Journal of Laboratory Hematology, 2020, 42, e270-e273.	0.7	8
57	RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features. Blood Advances, 2020, 4, 3677-3687.	2.5	51
58	Shared and Distinctive Ultrastructural Abnormalities Expressed by Megakaryocytes in Bone Marrow and Spleen From Patients With Myelofibrosis. Frontiers in Oncology, 2020, 10, 584541.	1.3	4
59	Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning. Blood, 2020, 135, 287-292.	0.6	34
60	Polycythemia vera: the current status of preclinical models and therapeutic targets. Expert Opinion on Therapeutic Targets, 2020, 24, 615-628.	1.5	5
61	An agenda for future research projects in polycythemia vera and essential thrombocythemia. Haematologica, 2020, 105, 1999-2003.	1.7	6
62	Genetic lesions disrupting calreticulin 3â€²â€untranslated region in <scp>JAK2</scp> mutationâ€negative polycythemia <scp>vera</scp>. American Journal of Hematology, 2020, 95, E263.	2.0	9
63	Drug-Related Cutaneous Adverse Events in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Literature Review. International Journal of Molecular Sciences, 2020, 21, 3900.	1.8	12
64	Current management strategies for polycythemia vera and essential thrombocythemia. Blood Reviews, 2020, 42, 100714.	2.8	35
65	Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice. Annals of Hematology, 2020, 99, 65-72.	0.8	13
66	Essential Thrombocythemia and Acquired von Willebrand Syndrome: The Shadowlands between Thrombosis and Bleeding. Cancers, 2020, 12, 1746.	1.7	18
67	Thrombocytopenia in patients with myelofibrosis: management options in the era of JAK inhibitor therapy. Leukemia and Lymphoma, 2020, 61, 1535-1547.	0.6	6
68	Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis. Blood Cancer Journal, 2020, 10, 21.	2.8	35
69	Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature. Clinical and Experimental Medicine, 2020, 20, 313-320.	1.9	5
70	Stem cell transplant for the treatment of myelofibrosis. Expert Review of Hematology, 2020, 13, 363-374.	1.0	4
71	Mutationâ€enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. British Journal of Haematology, 2020, 189, 291-302.	1.2	134
72	A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: Morphological and molecular characteristics of a highly aggressive disease. American Journal of Hematology, 2020, 95, 1622-1624.	2.0	1

#	Article	IF	Citations
73	Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. Blood, 2020, 135, 381-386.	0.6	18
74	The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (pts) with Myelofibrosis (MF) and Low Platelet (PLT) Count (50 Ã— 109/L to < 100 Ã— 109/L) at Baseline. Blood, 2020, 136, 4-5.	0.6	6
75	Long-Term Effect of Ruxolitinib (RUX) in Inadequately Controlled Polycythemia Vera (PV) without Splenomegaly: 5-Year Results from the Phase 3 Response-2 Study. Blood, 2020, 136, 40-41.	0.6	5
76	Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants. Scientific Reports, 2019, 9, 10558.	1.6	31
77	Systemic mastocytosis associated with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Report of three cases. Hematological Oncology, 2019, 37, 628-633.	0.8	3
78	Long Reads, Short Time: Feasibility of Prenatal Sample Karyotyping by Nanopore Genome Sequencing. Clinical Chemistry, 2019, 65, 1605-1608.	1.5	4
79	Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. Cancer Medicine, 2019, 8, 4089-4092.	1.3	16
80	Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative. American Journal of Hematology, 2019, 94, E239-E242.	2.0	3
81	Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. Leukemia, 2019, 33, 1996-2005.	3.3	67
82	Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation. Blood, 2019, 133, 2802-2808.	0.6	12
83	Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis. Haematologica, 2019, 104, e551-e554.	1.7	27
84	Myelodysplasia as assessed by multiparameter flow cytometry refines prognostic stratification provided by genotypic risk in systemic mastocytosis. American Journal of Hematology, 2019, 94, 845-852.	2.0	5
85	CircRNAs Are Here to Stay: A Perspective on the MLL Recombinome. Frontiers in Genetics, 2019, 10, 88.	1.1	19
86	Nano-GLADIATOR: real-time detection of copy number alterations from nanopore sequencing data. Bioinformatics, 2019, 35, 4213-4221.	1.8	15
87	Validation of the Mayo alliance prognostic system for mastocytosis. Blood Cancer Journal, 2019, 9, 18.	2.8	6
88	The JAK2 46/1 (GGCC) MPNâ€predisposing haplotype: A risky haplotype, after all. American Journal of Hematology, 2019, 94, 283-285.	2.0	3
89	PS1458 RISK FACTORS AND OUTCOME OF ACUTE MYELOID LEUKEMIA SECONDARY TO POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT. HemaSphere, 2019, 3, 671.	1.2	2
90	Multi-Lineage Dysplasia Assessment By Immunophenotype in Myeloproliferative Neoplasms (MPN): Correlation with Disease' Variant, Clinical Features and Molecular Genetics. Blood, 2019, 134, 1668-1668.	0.6	1

#	Article	IF	Citations
91	Frequency of Thrombosis Is Higher in MPN Patients Who Develop Second Cancer Than in Controls. Blood, 2019, 134, 4170-4170.	0.6	2
92	Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs). Blood, 2019, 134, 2968-2968.	0.6	4
93	Validation of the International Prognostic Score for Thrombosis in Essential Thrombocythemia (IPSET) in Patients with Pre-Fibrotic Primary Myelofibrosis. Blood, 2019, 134, 1657-1657.	0.6	0
94	Final Analysis at 5 Years Follow up of Patients with MPN-Associated Splanchnic Vein Thrombosis Treated with Ruxolitinib in a Phase 2 Study. Blood, 2019, 134, 1662-1662.	0.6	0
95	Impact of Disease Burden in Myelofibrosis Patients: A Sub Analysis from Italian Romei Observational Study. Blood, 2019, 134, 4188-4188.	0.6	0
96	Dysregulated IL-6/GP130/JAK Signaling in Calreticulin Mutated Myeloproliferative Neoplasms (MPN). Blood, 2019, 134, 471-471.	0.6	0
97	Shared and Distinctive Ultrastructural Abnormalities Expressed By Megakaryocytes in Bone Marrow and Spleen from Patients with Primary Myelofibrosis. Blood, 2019, 134, 4209-4209.	0.6	0
98	Adherence to Treatment in Myelofibrosis Patients: Preliminary Results from Italian Romei Observational Study. Blood, 2019, 134, 4179-4179.	0.6	1
99	Impact of Bone Marrow Fibrosis Grade in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis. a Study of the Mysec Group. Blood, 2019, 134, 2946-2946.	0.6	0
100	GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia, 2018, 32, 1631-1642.	3.3	213
101	Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. Haematologica, 2018, 103, e392-e394.	1.7	31
102	Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies. Annals of Hematology, 2018, 97, 617-627.	0.8	23
103	Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia, 2018, 32, 1200-1210.	3.3	101
104	The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer Journal, 2018, 8, 15.	2.8	404
105	The spleen of patients with myelofibrosis harbors defective mesenchymal stromal cells. American Journal of Hematology, 2018, 93, 615-622.	2.0	8
106	Calreticulin Affects Hematopoietic Stem/Progenitor Cell Fate by Impacting Erythroid and Megakaryocytic Differentiation. Stem Cells and Development, 2018, 27, 225-236.	1.1	17
107	JAK2 exon 12 mutated polycythemia vera: Mayoâ€Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease. American Journal of Hematology, 2018, 93, E93-E96.	2.0	27
108	Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. Leukemia Research, 2018, 69, 100-102.	0.4	13

#	Article	IF	Citations
109	Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. Blood Cancer Journal, 2018, 8, 25.	2.8	26
110	Clonal architecture of JAK2<scp>V617F</scp> mutated cells during treatment with ruxolitinib. Hematological Oncology, 2018, 36, 357-359.	0.8	0
111	Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients. Leukemia, 2018, 32, 438-449.	3.3	26
112	Driver mutations and prognosis in primary myelofibrosis: Mayoâ€Careggi MPN alliance study of 1,095 patients. American Journal of Hematology, 2018, 93, 348-355.	2.0	94
113	Polycythemia vera and essential thrombocythemia: algorithmic approach. Current Opinion in Hematology, 2018, 25, 112-119.	1.2	12
114	Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide. British Journal of Haematology, 2018, 182, 279-284.	1.2	3
115	MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. Journal of Clinical Oncology, 2018, 36, 310-318.	0.8	373
116	MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis. Journal of Clinical Oncology, 2018, 36, 1769-1770.	0.8	249
117	Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea. Blood Cancer Journal, 2018, 8, 122.	2.8	25
118	Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. Blood Cancer Journal, 2018, 8, 89.	2.8	13
119	Role of TGF â€Î²1/miRâ€382â€5p/ SOD 2 axis in the induction of oxidative stress in CD 34+ cells from primary myelofibrosis. Molecular Oncology, 2018, 12, 2102-2123.	2.1	19
120	Classification and Personalized Prognosis in Myeloproliferative Neoplasms. New England Journal of Medicine, 2018, 379, 1416-1430.	13.9	442
121	Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. Blood Advances, 2018, 2, 2964-2972.	2.5	68
122	Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. Annals of Hematology, 2018, 97, 1591-1600.	0.8	53
123	Myelofibrosis Treatment Algorithm 2018. Blood Cancer Journal, 2018, 8, 72.	2.8	31
124	Mutation-Enhanced International Prognostic Systems for Essential Thrombocythemia (MIPSS-ET) and Polycythemia Vera (MIPSS-PV). Blood, 2018, 132, 578-578.	0.6	5
125	Mutations and Thrombosis in Essential Thrombocythemia and Polycythemia Vera: Mayo-Careggi Alliance Study. Blood, 2018, 132, 3040-3040.	0.6	1
126	Risk Factors for Secondary Cancer in a Case-Control Study on 1,259 Patients with Myeloproliferative Neoplasms. Blood, 2018, 132, 4279-4279.	0.6	1

#	Article	IF	Citations
127	Calreticulin Ins5 and Del52 Mutations Impair Unfolded Protein and Oxidative Stress Responses in Hematopoietic Cells. Blood, 2018, 132, 4332-4332.	0.6	1
128	Ruxolitinib for the Treatment of Inadequately Controlled Polycythemia Vera without Splenomegaly: 156-Week Follow-up from the Phase 3 Response-2 Study. Blood, 2018, 132, 1754-1754.	0.6	3
129	JAK2V617F Variant Allele Frequency Identifies Patients with Polycythemia Vera (PV) at High Risk for Venous Thrombosis. Blood, 2018, 132, 1776-1776.	0.6	0
130	Comparative Genomic and Expression Analysis of Chronic and Blast-Phase Cells in Patients with Myeloproliferative Neoplasms. Blood, 2018, 132, 1777-1777.	0.6	0
131	Large Genomic Alterations Occurring in the Transition from Chronic to Blast Phase of Chronic Myeloproliferative Neoplasms. Blood, 2018, 132, 3028-3028.	0.6	0
132	Real-World Management of Myelofibrosis with Ruxolitinib: Initial Analysis of an Italian Observational Study (ROMEI). Blood, 2018, 132, 4312-4312.	0.6	0
133	Absence of Calreticulin Phenocopies Cellular Abnormalities Induced By Calreticulin Exon-9 Mutation in Myeloproliferative Neoplasms. Blood, 2018, 132, 1780-1780.	0.6	0
134	Solid Tumors in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Study on 2220 Patients. Blood, 2018, 132, 3039-3039.	0.6	0
135	Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. Journal of Hematology and Oncology, 2017, 10, 54.	6.9	41
136	Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. Annals of Hematology, 2017, 96, 1113-1120.	0.8	68
137	Recommendations for molecular testing in classical Ph1-neg myeloproliferative disordersâ€“A consensus project of the Italian Society of Hematology. Leukemia Research, 2017, 58, 63-72.	0.4	25
138	A lifeâ€threatening ruxolitinib discontinuation syndrome. American Journal of Hematology, 2017, 92, 833-838.	2.0	38
139	A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia, 2017, 31, 2726-2731.	3.3	242
140	Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood, 2017, 129, 3227-3236.	0.6	137
141	Clinical Phenotype and Genotype Correlations with Time to Progression into Post Polycythemia Vera and Post Essential Thrombocythemia Myelofibrosis. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S354-S355.	0.2	0
142	Traffic lights for ruxolitinib. Blood, 2017, 130, 1075-1077.	0.6	8
143	Gender and survival in essential thrombocythemia: A twoâ€center study of 1,494 patients. American Journal of Hematology, 2017, 92, 1193-1197.	2.0	27
144	The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Annals of Hematology, 2017, 96, 1653-1665.	0.8	92

#	Article	IF	Citations
145	CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles. Blood Cancer Journal, 2017, 7, 638.	2.8	27
146	Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms. American Journal of Hematology, 2017, 92, 187-195.	2.0	41
147	Driver mutationsâ€™ effect in secondary myelofibrosis: an international multicenter study based on 781 patients. Leukemia, 2017, 31, 970-973.	3.3	41
148	What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?. Hematology American Society of Hematology Education Program, 2017, 2017, 480-488.	0.9	16
149	Role of miR-34a-5p in Hematopoietic Progenitor Cells Proliferation and Fate Decision: Novel Insights into the Pathogenesis of Primary Myelofibrosis. International Journal of Molecular Sciences, 2017, 18, 145.	1.8	14
150	miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6. Oncotarget, 2017, 8, 21380-21397.	0.8	13
151	Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation inJAK2V617Fmutated cells through PP2A/CIP2A axis. Oncotarget, 2017, 8, 96710-96724.	0.8	32
152	Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Advances, 2016, 1, 21-30.	2.5	243
153	Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis. Journal of Experimental Medicine, 2016, 213, 1479-1496.	4.2	101
154	Germline transmission of LNKE208Q variant in a family with myeloproliferative neoplasms. American Journal of Hematology, 2016, 91, E356.	2.0	13
155	Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. American Journal of Hematology, 2016, 91, 918-922.	2.0	47
156	A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells. Blood Cancer Journal, 2016, 6, e439-e439.	2.8	16
157	STAT1 activation in association with JAK2 exon 12 mutations. Haematologica, 2016, 101, e15-e19.	1.7	11
158	The prognostic impact of bone marrow fibrosis in primary myelofibrosis. American Journal of Hematology, 2016, 91, E454-5.	2.0	15
159	Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica, 2016, 101, 926-931.	1.7	118
160	Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients. Blood Cancer Journal, 2016, 6, e493-e493.	2.8	80
161	Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group. American Journal of Hematology, 2016, 91, 681-686.	2.0	80
162	Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in primary myelofibrosis. International Journal of Cancer, 2016, 138, 1657-1669.	2.3	6

#	Article	IF	Citations
163	Ruxolitinib is an effective treatment for <scp>CALR</scp>â€positive patients with myelofibrosis. British Journal of Haematology, 2016, 173, 938-940.	1.2	36
164	Tie2 Expressing Monocytes in the Spleen of Patients with Primary Myelofibrosis. PLoS ONE, 2016, 11, e0156990.	1.1	3
165	MAF Induces Inflammatory Mediators Involved in the Pathogenesis of Primary Myelofibrosis. Blood, 2016, 128, 3132-3132.	0.6	0
166	MiR-494-3p Overexpression Leads to SOCS6 Downregulation and Supports Megakaryocytopoiesis in Primary Myelofibrosis CD34+ Hematopoietic Stem/Progenitor Cells. Blood, 2016, 128, 4272-4272.	0.6	0
167	The Impact of Myeloproliferative Neoplasms (MPNs) on Patients' Quality of Life and Productivity: Results from the International MPN Landmark Survey. Blood, 2016, 128, 4267-4267.	0.6	0
168	Differences in Clinical and Molecular Characteristics and Outcome in Prefibrotic and Overt Primary Myelofibrosis According to 2016 WHO Criteria. a Study on 639 Patients of the Agimm Group. Blood, 2016, 128, 943-943.	0.6	1
169	Prognotic Impact of Mutations in Systemic Mastocytosis. Blood, 2016, 128, 1953-1953.	0.6	0
170	Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis. Genomics Data, 2015, 5, 1-2.	1.3	5
171	JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib. Blood, 2015, 125, 3352-3353.	0.6	41
172	Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+ Cells. PLoS ONE, 2015, 10, e0140445.	1.1	20
173	Effect of Mutation Order on Myeloproliferative Neoplasms. New England Journal of Medicine, 2015, 372, 601-612.	13.9	467
174	Hemoglobin levels and circulating blasts are two easily evaluable diagnostic parameters highly predictive of leukemic transformation in primary myelofibrosis. Leukemia Research, 2015, 39, 314-317.	0.4	11
175	Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial. Blood Cancer Journal, 2015, 5, e286-e286.	2.8	7
176	What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?. Current Hematologic Malignancy Reports, 2015, 10, 380-387.	1.2	1
177	Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis. Blood Cancer Journal, 2015, 5, e360-e360.	2.8	72
178	Profound parental bias associated with chromosome 14 acquired uniparental disomy indicates targeting of an imprinted locus. Leukemia, 2015, 29, 2069-2074.	3.3	13
179	Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. Nature Communications, 2015, 6, 6691.	5.8	145
180	CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis. Leukemia, 2015, 29, 1209-1210.	3.3	31

#	Article	IF	Citations
181	Ruxolitinibâ€induced reversal of alopecia universalis in a patient with essential thrombocythemia. American Journal of Hematology, 2015, 90, 82-83.	2.0	56
182	Abnormal expression patterns ofWT1-as, MEG3andANRILlong non-coding RNAs in CD34+ cells from patients with primary myelofibrosis and their clinical correlations. Leukemia and Lymphoma, 2015, 56, 492-496.	0.6	14
183	A Study of the Role of Antiplatelet Therapy in the Prevention of Thrombosis in Patients with Calr-Mutated Low Risk Essential Thrombocythemia. Blood, 2015, 126, 1602-1602.	0.6	2
184	Driver Mutations and Prognosis in 1118 Patients with Primary Myelofibrosis. Blood, 2015, 126, 2801-2801.	0.6	1
185	Long Term Follow up of a Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm. Blood, 2015, 126, 2803-2803.	0.6	2
186	Prognostic Impact of Bone Marrow Fibrosis in Primary Myelofibrosis: A Study of Agimm Group on 540 Patients. Blood, 2015, 126, 351-351.	0.6	1
187	Mutational Profile of Patients with Polycythemia Vera Treated with Ruxolitinib in the Phase III Controlled Response Study. Blood, 2015, 126, 4087-4087.	0.6	2
188	Mutational Landscape of Patients with Myelofibrosis That Do Not Harbor Mutations in JAK2, MPL and Calreticulin Driver Genes. Blood, 2015, 126, 4091-4091.	0.6	2
189	A Greater Mutational Complexity May Contribute to the Differential Prognostic Impact of Type 1/Type 1-like Versus Type 2/Type2-like Calreticulin Mutations in Primary Myelofibrosis. Blood, 2015, 126, 1627-1627.	0.6	0
190	JAK2V617F Clonal Architecture in MPNs during JAK2 Inhibitor Treatment. Blood, 2015, 126, 1630-1630.	0.6	0
191	Impact of Underlying Mutational Profile, and Changes during Treatment, in MPN Patients Treated with JAK Inhibitors. Blood, 2015, 126, 353-353.	0.6	0
192	IWG-MRT 2013 Criteria-Based Assessment of Response Among 83 Patients with Myelofibrosis Treated with JAK Inhibitors: Experience of Two Centers. Blood, 2015, 126, 1615-1615.	0.6	0
193	Givinostat for the treatment of polycythemia vera. Expert Opinion on Orphan Drugs, 2014, 2, 841-850.	0.5	1
194	Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood, 2014, 124, 1062-1069.	0.6	340
195	A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer, 2014, 120, 513-520.	2.0	165
196	Mutational analysis of BCORL1 in the leukemic transformation of chronic myeloproliferative neoplasms. Annals of Hematology, 2014, 93, 523-524.	0.8	4
197	Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood, 2014, 123, 2157-2160.	0.6	115
198	CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia, 2014, 28, 1494-1500.	3.3	248

#	Article	IF	Citations
199	Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients. American Journal of Hematology, 2014, 89, 588-590.	2.0	75
200	Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients. American Journal of Hematology, 2014, 89, E121-4.	2.0	176
201	Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms. Expert Review of Hematology, 2014, 7, 423-425.	1.0	7
202	CALR mutations in myeloproliferative neoplasms: Hidden behind the reticulum. American Journal of Hematology, 2014, 89, 453-456.	2.0	34
203	Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms. Leukemia, 2014, 28, 1052-1059.	3.3	66
204	Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood, 2014, 123, 1552-1555.	0.6	346
205	The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia, 2014, 28, 1804-1810.	3.3	263
206	Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. Leukemia, 2014, 28, 1811-1818.	3.3	75
207	Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood, 2014, 124, 2507-2513.	0.6	575
208	miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis. Blood, 2014, 124, e21-e32.	0.6	105
209	Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. Blood, 2014, 124, 2611-2612.	0.6	79
210	Post-Polycythemia and Post-Thrombocythemia Myelofibrosis Have Distinctive Clinical Phenotypes: An International Multicenter Study on 718 Patients. Blood, 2014, 124, 1824-1824.	0.6	9
211	A New International Multicenter-Based Model to Predict Survival in Myelofibrosis Secondary to Polycythemia and Thrombocythemia: The Mysec Prognostic Model (MYSEC-PM). Blood, 2014, 124, 1826-1826.	0.6	4
212	Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasms: A Study of the AGIMM & IWG-MRT Groups in 519 Subjects. Blood, 2014, 124, 3163-3163.	0.6	1
213	A Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm: A Study from the AGIMM Group. Blood, 2014, 124, 3192-3192.	0.6	1
214	Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project. Blood, 2014, 124, 405-405.	0.6	47
215	Integration of Mutations and Karyotype Towards a Genetics-Based Prognostic Scoring System (GPSS) for Primary Myelofibrosis. Blood, 2014, 124, 406-406.	0.6	27
216	JAK2V617F Complete Molecular Remission in Long-Term Follow-up of Patients with Polycythemia Vera and Essential Thrombocythemia Treated with Ruxolitinib. Blood, 2014, 124, 3185-3185.	0.6	0

#	Article	IF	Citations
217	Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group. Blood, 2014, 124, 3179-3179.	0.6	0
218	Calreticulin Mutation Does Not Modify the International Prognostic Score for Predicting the Risk of Thrombosis Among 1,150 Patients with Essential Thrombocythemia. Blood, 2014, 124, 404-404.	0.6	0
219	Impact of Mutation Status of ASXL1, EZH2, SRSF2, IDH1/2 on Clinical Phenotype and Prognosis in Patients with Post-Polycythemia and Post-Essential Thrombocythemia Myelofibrosis: An AGIMM Study. Blood, 2014, 124, 1867-1867.	0.6	0
220	A Retrospective Analysis of Safety and Efficacy of Ruxolitinib in CALR-Positive Patients with Myelofibrosis. Blood, 2014, 124, 1853-1853.	0.6	0
221	Struggling with myelofibrosis-associated anemia. Leukemia Research, 2013, 37, 1429-1431.	0.4	8
222	Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. Leukemia, 2013, 27, 2032-2039.	3.3	96
223	SomaticCALRMutations in Myeloproliferative Neoplasms with NonmutatedJAK2. New England Journal of Medicine, 2013, 369, 2391-2405.	13.9	1,556
224	Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis. Leukemia, 2013, 27, 2084-2086.	3.3	51
225	Rationale for Targeting the PI3K/Akt/mTOR Pathway in Myeloproliferative Neoplasms. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, S307-S309.	0.2	45
226	Mutations and prognosis in primary myelofibrosis. Leukemia, 2013, 27, 1861-1869.	3.3	653
227	Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis. Haematologica, 2013, 98, e101-e102.	1.7	24
228	JAK2 Mutation-Related Disease and Thrombosis. Seminars in Thrombosis and Hemostasis, 2013, 39, 496-506.	1.5	40
229	The <scp>ERCC2 G</scp>ln/<scp>G</scp>ln polymorphism at codon 751 is not associated with leukaemic transformation in primary myelofibrosis. British Journal of Haematology, 2013, 162, 424-427.	1.2	4
230	Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. Blood, 2013, 121, 360-368.	0.6	102
231	Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. Blood, 2013, 121, 4388-4395.	0.6	83
232	Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis. Blood, 2013, 122, 104-104.	0.6	3
233	Impact Of Prognostically Detrimental Mutations (ASXL1, EZH2, SRSF2, IDH1/2) On Outcomes In Patients With Myelofibrosis Treated With Ruxolitinib In COMFORT-II. Blood, 2013, 122, 107-107.	0.6	2
234	Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasms. A Study Of The IWG-MRT In 475 Subjects. Blood, 2013, 122, 1582-1582.	0.6	1

#	Article	IF	Citations
235	A Phase 2 Study Of Ruxolitinib In Patients With Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasm. Preliminary Results. Blood, 2013, 122, 1583-1583.	0.6	4
236	The Genomic Landscape of Myeloproliferative Neoplasms: Somatic Calr Mutations in the Majority of JAK2-Wildtype Patients. Blood, 2013, 122, LBA-2-LBA-2.	0.6	1
237	mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms. PLoS ONE, 2013, 8, e54826.	1.1	80
238	Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. PLoS ONE, 2013, 8, e77819.	1.1	9
239	Normal Karyotype Primary Myelofibrosis (NK-PMF): Clinical and Molecular Prognostication In 690 Patients. Blood, 2013, 122, 1587-1587.	0.6	3
240	Integrative Analysis Of mRNA/miRNA Expression Profiles Identified JARID2 As a Shared Target Of Deregulated Mirnas In Primary Myelofibrosis. Blood, 2013, 122, 1600-1600.	0.6	0
241	Targeted Cancer Exome Sequencing Discovers Novel Recurrent Mutations In MPN. Blood, 2013, 122, 4099-4099.	0.6	0
242	Somatic and Germ-Line Molecular Characteristics Of Prefibrotic Myelofibrosis. Blood, 2013, 122, 4058-4058.	0.6	0
243	Improving Survival Trends in Primary Myelofibrosis: An International Study. Journal of Clinical Oncology, 2012, 30, 2981-2987.	0.8	105
244	BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques. Future Oncology, 2012, 8, 575-593.	1.1	4
245	Risk of second cancers in chronic myeloproliferative neoplasms. Blood, 2012, 119, 3861-3862.	0.6	14
246	JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone. Blood, 2012, 120, 2704-2707.	0.6	94
247	Characterization and discovery of novel miRNAs and moRNAs in JAK2V617F-mutated SET2 cells. Blood, 2012, 119, e120-e130.	0.6	34
248	Hydroxyureaâ€related toxicity in 3,411 patients with Ph'â€negative MPN. American Journal of Hematology, 2012, 87, 552-554.	2.0	105
249	Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. American Journal of Hematology, 2012, 87, 245-250.	2.0	107
250	Regulatory Mrna/Microrna Networks in CD34+ Cells From Primary Myelofibrosis.. Blood, 2012, 120, 2854-2854.	0.6	0
251	Prognostic Impact of Mutations in a Large Series of Patients with Myelofibrosis. Blood, 2012, 120, 431-431.	0.6	19
252	Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients. Leukemia, 2011, 25, 1834-1839.	3.3	59

#	Article	IF	Citations
253	JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment. Therapeutic Advances in Hematology, 2011, 2, 21-32.	1.1	82
254	Overexpression of microRNA-16-2 contributes to the abnormal erythropoiesis in polycythemia vera. Blood, 2011, 117, 6923-6927.	0.6	26
255	Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood, 2011, 118, 2069-2076.	0.6	144
256	EZH2 mutational status predicts poor survival in myelofibrosis. Blood, 2011, 118, 5227-5234.	0.6	242
257	Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood, 2011, 118, 167-176.	0.6	153
258	Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica, 2011, 96, 315-318.	1.7	160
259	FLT3-Mediated p38â€“MAPK Activation Participates in the Control of Megakaryopoiesis in Primary Myelofibrosis. Cancer Research, 2011, 71, 2901-2915.	0.4	46
260	Prognostic Impact of EZH2 and ASXL1 Mutation in Myelofibrosis. Blood, 2011, 118, 2811-2811.	0.6	4
261	Systematic Evaluation of DNA-Based Quantitative-Polymerase Chain Reaction (Q-PCR) Assays to Track Treatment Response in Patients with JAK2-V617F Associated Myeloproliferative Neoplasms: A Joint European LeukemiaNet/ MPN&MPNr-EuroNet Study. Blood, 2011, 118, 2812-2812.	0.6	2
262	Inhibitors of PI3K/Akt and/or mTOR Inhibit the Growth of Cells of Myeloproliferative Neoplasms and Synergize with JAK2 Inhibitor and Interferon,. Blood, 2011, 118, 3835-3835.	0.6	7
263	Treatment with Ruxolitinib (INCB018424) Induced Changes of Microrna Expression in Granulocytes of Patients with Polycythemia Vera and Essential Thrombocythemia,. Blood, 2011, 118, 3852-3852.	0.6	1
264	Interlaboratory Quality Control Round of MPL Mutation Detection in Fourteen European Laboratories: A MPN&MPNr-EuroNet Study,. Blood, 2011, 118, 3859-3859.	0.6	1
265	C-Myb Transactivates the Expression of Erythroid Hsa-miR16-2 Gene,. Blood, 2011, 118, 3386-3386.	0.6	0
266	Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. American Journal of Hematology, 2010, 85, 97-100.	2.0	48
267	Advances in understanding and management of polycythemia vera. Current Opinion in Oncology, 2010, 22, 636-641.	1.1	8
268	Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms. Haematologica, 2010, 95, 2153-2156.	1.7	19
269	Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. Haematologica, 2010, 95, 1435-1438.	1.7	41
270	Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. Annals of Hematology, 2010, 89, 141-146.	0.8	39

#	Article	IF	Citations
271	Phase I/II study of singleâ€agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition. American Journal of Hematology, 2010, 85, 616-619.	2.0	18
272	CXCR4â€independent rescue of the myeloproliferative defect of the gata1^{low} myelofibrosis mouse model by AplidinÂ®. Journal of Cellular Physiology, 2010, 225, 490-499.	2.0	16
273	A pilot study of the Histoneâ€Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. British Journal of Haematology, 2010, 150, 446-455.	1.2	202
274	IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia, 2010, 24, 1302-1309.	3.3	300
275	Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. Leukemia, 2010, 24, 1533-1537.	3.3	22
276	High Frequency of Endothelial Colony Forming Cells Marks a Non-Active Myeloproliferative Neoplasm with High Risk of Splanchnic Vein Thrombosis. PLoS ONE, 2010, 5, e15277.	1.1	30
277	A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood, 2010, 115, 1703-1708.	0.6	805
278	Thrombosis in primary myelofibrosis: incidence and risk factors. Blood, 2010, 115, 778-782.	0.6	216
279	A Phase 1/2 Study of RAD001, a mTOR Inhibitor, In Patients with Myelofibrosis: Final Results. Blood, 2010, 116, 314-314.	0.6	7
280	LNK Mutation Studies In Chronic- and Blast-Phase Myeloproliferative Neoplasms and JAK2 Mutation-Negative Erythrocytosis. Blood, 2010, 116, 4105-4105.	0.6	4
281	Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms. F1000 Medicine Reports, 2010, 2, .	2.9	3
282	Characterization of Targets of Plitidepsin In JAK2V617F-Mutated Cells From Myeloproliferative Neoplasms. Blood, 2010, 116, 4093-4093.	0.6	0
283	Increased Risk of Lymphoid Neoplasms in Patients with Philadelphia Chromosomeâ€"Negative Myeloproliferative Neoplasms. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2068-2073.	1.1	100
284	JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis. Haematologica, 2009, 94, 144-146.	1.7	35
285	Advances in Understanding and Management of Myeloproliferative Neoplasms. Ca-A Cancer Journal for Clinicians, 2009, 59, 171-191.	157.7	170
286	Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives. Journal of Cellular and Molecular Medicine, 2009, 13, 1437-1450.	1.6	23
287	JAK2V617F allele burden and thrombosis: A direct comparison in essential thrombocythemia and polycythemia vera. Experimental Hematology, 2009, 37, 1016-1021.	0.2	89
288	JAK2V617F mutation screening in patients with retinal vein thrombosis or recurrent fetal loss. Thrombosis Research, 2009, 124, 377-378.	0.8	1

#	Article	IF	Citations
289	Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood, 2009, 114, 1477-1483.	0.6	196
290	Treatment options for essential thrombocythemia and polycythemia vera. Expert Review of Hematology, 2009, 2, 41-55.	1.0	6
291	The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera. Haematologica, 2009, 94, 1537-1545.	1.7	58
292	The mTOR Inhibitor, RAD001, Inhibits the Growth of Cells From Patients with Myeloproliferative Neoplasms.. Blood, 2009, 114, 2914-2914.	0.6	8
293	Thrombosis in Primary Myelofibrosis: Incidence and Risk Factors.. Blood, 2009, 114, 2915-2915.	0.6	1
294	RAD001, An Inhibitor of mTOR, Shows Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (PPV/PET) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.6	14
295	High Frequency of Circulating Endothelial Colony Forming Cells (ECFCs) in Myeloproliferative Neoplasms (MPNs) Is Associated with Diagnosis of Prefibrotic Myelofibrosis, History of Splanchnic Vein Thrombosis, and Vascular Splenomegaly.. Blood, 2009, 114, 309-309.	0.6	2
296	Changes of JAK2 V617F Allele Burden Over Time in Patients with Polycythemia Vera or Essential Thrombocythemia: A Retrospective Study of 172 Patients.. Blood, 2009, 114, 1892-1892.	0.6	0
297	A Dynamic Prognostic Model to Predict Survival in Primary Myelofibrosis: a Study of the International Working Group for Myeloproliferative Neoplasm Research and Treatment (IWG-MRT).. Blood, 2009, 114, 3891-3891.	0.6	0
298	Plitidepsin Inhibits the Growth of Cells Harboring JAK2V617F Mutation.. Blood, 2009, 114, 3907-3907.	0.6	0
299	Deranged MicroRNA 16-2 Expression Contributes to Erythropoiesis in Polycythemia Vera.. Blood, 2009, 114, 3896-3896.	0.6	0
300	Mesenchymal stem cells from JAK2V617F mutant patients with primary myelofibrosis do not harbor JAK2 mutant allele. Leukemia Research, 2008, 32, 516-517.	0.4	17
301	Hypermethylation ofCXCR4Promoter in CD34+ Cells from Patients with Primary Myelofibrosis. Stem Cells, 2008, 26, 1920-1930.	1.4	91
302	Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia, 2008, 22, 1299-1307.	3.3	273
303	No role for CXCL12â€“G801A polymorphism in the development of extramedullary disease in acute myeloid leukemia. Leukemia, 2008, 22, 669-671.	3.3	7
304	Animal Models of Myelofibrosis. , 2008, , 713-723.		1
305	A Sensitive Detection Method for MPLW515L or MPLW515K Mutation in Chronic Myeloproliferative Disorders with Locked Nucleic Acid-Modified Probes and Real-Time Polymerase Chain Reaction. Journal of Molecular Diagnostics, 2008, 10, 435-441.	1.2	47
306	Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica, 2008, 93, 41-48.	1.7	146

#	Article	IF	Citations
307	Leukocytosis and Risk Stratification Assessment in Essential Thrombocythemia. Journal of Clinical Oncology, 2008, 26, 2732-2736.	0.8	169
308	Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica, 2008, 93, 372-380.	1.7	316
309	Molecular pathophysiology of Philadelphia-negative myeloproliferative disorders: beyond JAK2 and MPL mutations. Haematologica, 2008, 93, 972-976.	1.7	25
310	Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood, 2008, 112, 844-847.	0.6	216
311	Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood, 2008, 112, 3135-3137.	0.6	100
312	A Phase 2A study of the Histone-Deacetylase Inhibitor ITF2357 in Patients with Jak2V617F Positive Chronic Myeloproliferative Neoplasms. Blood, 2008, 112, 100-100.	0.6	28
313	Dysregulated Expression of MicroRNA-16 Contributes to Abnormal Erythropoiesis in Patients with Polycythemia Vera. Blood, 2008, 112, 179-179.	0.6	2
314	Constitutively Activated and Hyper-Sensitive Basophils in Patients with Polycythemia Vera: Role of JAK2V617F Mutation and Correlation with Pruritus. Blood, 2008, 112, 3714-3714.	0.6	3
315	Clinical Relevance of JAK2V617F Allele Burden in Primary and Post-Polycythemic/Post-Thrombocythemic Myelofibrosis. Blood, 2008, 112, 2799-2799.	0.6	0
316	Similar Rate of Thrombosis in Essential Thrombocythemia and Polycythemia Vera Patients after Stratification for JAK2 V617F Allele Burden.. Blood, 2008, 112, 1745-1745.	0.6	0
317	Aplidin Improves Megakaryocytopoiesis and Halts Neo-Angiogenesis in the Gata1low Murine Model of Myelofibrosis. Blood, 2008, 112, 2787-2787.	0.6	6
318	B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. Haematologica, 2007, 92, 258-259.	1.7	26
319	Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood, 2007, 110, 840-846.	0.6	419
320	JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood, 2007, 110, 4030-4036.	0.6	233
321	Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance. Blood, 2007, 110, 4620-4621.	0.6	11
322	The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. Blood Cells, Molecules, and Diseases, 2007, 38, 280-286.	0.6	60
323	Insights into JAK2-V617F mutation in CML. Lancet Oncology, The, 2007, 8, 864-866.	5.1	50
324	Recurrent Venous Thrombosis in Patients with Polycythemia Vera and Essential Thrombocythemia. Clinical Leukemia, 2007, 1, 339-344.	0.2	1

#	Article	IF	Citations
325	Significance of CTLA-4 and CD14 genetic polymorphisms in clinical outcome after allogeneic stem cell transplantation. Bone Marrow Transplantation, 2007, 40, 1001-1002.	1.3	22
326	Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden. Leukemia, 2007, 21, 1952-1959.	3.3	328
327	Anaemia characterises patients with myelofibrosis harbouring MplW515L/Kmutation. British Journal of Haematology, 2007, 137, 244-247.	1.2	153
328	MicroRNA expression profile in granulocytes from primary myelofibrosis patients. Experimental Hematology, 2007, 35, 1708.e1-1708.e12.	0.2	71
329	Molecular Profiling of CD34+Cells in Idiopathic Myelofibrosis Identifies a Set of Disease-Associated Genes and Reveals the Clinical Significance of Wilms' Tumor Gene 1 (WT1). Stem Cells, 2007, 25, 165-173.	1.4	111
330	The Clinical Phenotype of Patients with Essential Thrombocythemia Harboring MPL 515W>L/K Mutation.. Blood, 2007, 110, 678-678.	0.6	15
331	Hypermethylation of CXCR4 Promoter, and Its Reactivation by Hypomethylating Agent, in CD34+ Cells from Primary Myelofibrosis Patients. Blood, 2007, 110, 1545-1545.	0.6	0
332	Inconsistencies in the association between the JAK2V617F mutation and PRV-1 over-expression among the chronic myeloproliferative diseases. British Journal of Haematology, 2006, 132, 652-654.	1.2	11
333	A quantitative assay for JAK2V617F mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis. Leukemia, 2006, 20, 1055-1060.	3.3	68
334	The size of duplication does not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patients. Leukemia, 2006, 20, 2074-2076.	3.3	51
335	Differential Amplification of Murine Bipotent Megakaryocytic/Erythroid Progenitor and Precursor Cells During Recovery from Acute and Chronic Erythroid Stress. Stem Cells, 2006, 24, 337-348.	1.4	25
336	Influence of the Jak2V617F Mutational Load at Diagnosis on Major Clinical Aspects in Patients with Polycythemia Vera.. Blood, 2006, 108, 5-5.	0.6	14
337	Role of extracorporeal photochemotherapy in patients with refractory chronic graft-versus-host disease. British Journal of Haematology, 2005, 130, 271-275.	1.2	63
338	Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia, 2005, 19, 1847-1849.	3.3	236
339	Abnormalities of GATA-1 in Megakaryocytes from Patients with Idiopathic Myelofibrosis. American Journal of Pathology, 2005, 167, 849-858.	1.9	62
340	Reduced Expression of CXCR4 on Circulating CD34+ Cells Is Associated with Hematopoietic Progenitor Cells (HPC) Mobilization in Patients with Myelofibrosis with Myeloid Metaplasia (MMM).. Blood, 2005, 106, 258-258.	0.6	3
341	Splenectomy Favours Development of Extramedullary Hematopoiesis in the GATA-1low Model of Myelofibrosis.. Blood, 2005, 106, 3513-3513.	0.6	0
342	PRV-1 , erythroid colonies and platelet Mpl are unrelated to thrombosis in essential thrombocythaemia. British Journal of Haematology, 2004, 127, 214-219.	1.2	21

#	Article	IF	Citations
343	The newly diagnosed patient with polycythemia vera. , 0, , 64-69.		0